CoChat
Sign Up
Cited by 147Neuropeptides and Animal PhysiologyStress Responses and CortisolNeurotransmitter Receptor Influence on Behavior

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

The Effect of Lateral Septum Corticotropin-Releasing Factor Receptor 2 Activation on Anxiety Is Modulated by Stress

Open access
Henry, Brook, Vale, Wylie, Markou, Athina·2006·The Journal of Neuroscience
DOI 10.1523/jneurosci.1494-06.2006PMC PMC6674509
Open this paper in CoChat — free accountOpen PDF

Abstract

Corticotropin-releasing factor (CRF), a 41 amino acid peptide, mediates endocrine, autonomic, and behavioral responses to stress. Whereas the CRF 1 receptor appears to contribute to anxiety associated with stress, the role of the CRF 2 receptor remains unclear and may depend on drug dose, brain location, or testing environment. Results involving treatments with selective CRF 2 receptor agonists or antagonists and the behavior of CRF 2 receptor knock-out mice suggest both anxiogenic and anxiolytic effects of CRF 2 receptor activation. The present study tested the hypothesis that the effect of CRF 2 receptor activation on anxiety depends on the stress level of the animal. The selective CRF 2 receptor agonist urocortin 2 was infused into the lateral septum of mice under low- or high-stress (30 min of immobilization) testing conditions, and then behavior in the light–dark box, open-field, and novel-object tests was assessed. In the low-stress environment, 240 pmol of septal urocortin 2 increased anxiety, but lower doses (0.48, 4.8, and 48 pmol) did not have consistent effects. However, in the high-stress condition, 48 pmol of septal urocortin 2 significantly increased anxiety compared with control in wild-type but not CRF 2 receptor knock-out mice in the light–dark box. Septal administration of the relatively selective CRF 2 antagonist astressin-2B, but not the CRF 1- selective antagonist antalarmin, blocked the anxiogenic effects of urocortin 2. Urocortin 2 infusion into the medial septum or lateral ventricle did not affect anxiety measures. These results indicate that the effect of septal CRF 2 receptor activation on anxiety is dependent on stress level.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1523/jneurosci.1494-06.2006

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Histological verification of the cannula injector placements. Cannula placement was verified after each experiment with the infusion of methylene blue dye as shown in the lateral ( b ) and medial ( c ) septum. Scale bars, 500 𝛍 m. a is an illustration of the septum showing successful cannula placements in the intermediate lateral septum (filled circles) and placements excluded from data analyses (open circles). d illustrates the central amygdala region targeted for antalarmin infusion, with an example section shown in e . LS, Lateral septum; MS, medial septum; LV, lateral ventricle; cc, corpus callosum; aca, anterior commissure, IC internal capsule; OP, optic tract; CEA, central nucleus of the amygdala; BLA, basolateral amygdala.
Figure 1 Histological verification of the cannula injector placements. Cannula placement was verified after each experiment with the infusion of methylene blue dye as shown in the lateral ( b ) and medial ( c ) septum. Scale bars, 500 𝛍 m. a is an illustration of the septum showing successful cannula placements in the intermediate lateral septum (filled circles) and placements excluded from data analyses (open circles). d illustrates the central amygdala region targeted for antalarmin infusion, with an example section shown in e . LS, Lateral septum; MS, medial septum; LV, lateral ventricle; cc, corpus callosum; aca, anterior commissure, IC internal capsule; OP, optic tract; CEA, central nucleus of the amygdala; BLA, basolateral amygdala.CC-BY-NC-SA · From the PDF
Image 2
CC-BY-NC-SA · From the PDF
Figure 4 Effect of septal urocortin 2 on anxiety is dependent on stress. Effect of septal urocortin 2 (48 pmol) in ICR mice treated with no stress or 30 min of immobilization stress on the following: a , latency to enter the light side of the light- dark box (seconds); b , total time spent in the light side of the light- dark box (seconds); c , locomotion in the open field (total square entries); d , percentage time in the center of the open field; e , locomotion in the open field with a novel object (total square entries; and f , percentage time spent in the center with a novel object. Transitions in the light- dark box and percentage center entries in open-field and novelobject tests are not shown. This dose of urocortin 2 had no effect on anxiety-like behavior in the low-stress condition but significantly increased anxiety-like behavior compared with vehicle in the light- dark box, open-field, and novel-object tests when combined with 30 min of immobilization stress. There was no difference in locomotion between vehicle- and peptide-treated mice in the stress condition. Data are presented as mean ± SEM. ** p < 0.01;*** p < 0.001.
Figure 4 Effect of septal urocortin 2 on anxiety is dependent on stress. Effect of septal urocortin 2 (48 pmol) in ICR mice treated with no stress or 30 min of immobilization stress on the following: a , latency to enter the light side of the light- dark box (seconds); b , total time spent in the light side of the light- dark box (seconds); c , locomotion in the open field (total square entries); d , percentage time in the center of the open field; e , locomotion in the open field with a novel object (total square entries; and f , percentage time spent in the center with a novel object. Transitions in the light- dark box and percentage center entries in open-field and novelobject tests are not shown. This dose of urocortin 2 had no effect on anxiety-like behavior in the low-stress condition but significantly increased anxiety-like behavior compared with vehicle in the light- dark box, open-field, and novel-object tests when combined with 30 min of immobilization stress. There was no difference in locomotion between vehicle- and peptide-treated mice in the stress condition. Data are presented as mean ± SEM. ** p < 0.01;*** p < 0.001.CC-BY-NC-SA · From the PDF
Figure 5 Septal urocortin 2 increased anxiety when combined with stress in CRF 2 receptor wild-type mice on a mixed C57BL/ 6 × 129 background. Effect of septal urocortin 2 (vehicle or 0.48, 4.8, or 48 pmol) in CRF 2 receptor wild-type mice treated with no stress or 30 min of immobilization stress on the following: a , latency to enter the light side of the light- dark box (seconds); b , total time spent in the light side of the light- dark box (seconds); c , locomotion in the open field (total square entries); d , percentage of time in the center of the open field; e , locomotion in the open field with a novel object (total square entries); and f , percentage of time spent in the center with a novel object. Transitions in the light- dark box and percentage of center entries in the open-field andnovel-object tests are not shown. Urocortin 2 did not affect anxiety-like behavior in the no-stress condition at any dose tested. In the stress condition, 48 pmol of urocortin 2 increased anxiety-like behavior in the light- dark box and novel-object tests; the 4.8 pmol dose increased anxiety in the novel-object test in the stress condition but not the no-stress condition. Data are presented as mean ± SEM. *** p < 0.001.
Figure 5 Septal urocortin 2 increased anxiety when combined with stress in CRF 2 receptor wild-type mice on a mixed C57BL/ 6 × 129 background. Effect of septal urocortin 2 (vehicle or 0.48, 4.8, or 48 pmol) in CRF 2 receptor wild-type mice treated with no stress or 30 min of immobilization stress on the following: a , latency to enter the light side of the light- dark box (seconds); b , total time spent in the light side of the light- dark box (seconds); c , locomotion in the open field (total square entries); d , percentage of time in the center of the open field; e , locomotion in the open field with a novel object (total square entries); and f , percentage of time spent in the center with a novel object. Transitions in the light- dark box and percentage of center entries in the open-field andnovel-object tests are not shown. Urocortin 2 did not affect anxiety-like behavior in the no-stress condition at any dose tested. In the stress condition, 48 pmol of urocortin 2 increased anxiety-like behavior in the light- dark box and novel-object tests; the 4.8 pmol dose increased anxiety in the novel-object test in the stress condition but not the no-stress condition. Data are presented as mean ± SEM. *** p < 0.001.CC-BY-NC-SA · From the PDF
Image 5
CC-BY-NC-SA · From the PDF
Figure 7 CRF 2 antagonist astressin-2B blocked the effect of urocortin 2 and stress on anxiety. Effect of septal CRF 2 receptor antagonist astressin-2B (24, 96, or 192 pmol) administered 10 min before urocortin 2 (48 pmol) in CRF 2 receptor wild-type mice treated with no stress or 30 min of immobilization stress on the following: a , latency to enter the light side of the light- dark box (seconds); b , total time spent in the light side of the light- dark box (seconds); c , locomotionintheopenfield(totalsquareentries); d , percentage of time in the center of the open field; e , locomotion in the open field with a novel object (total square entries); and f , percentage of time spent in the center with a novel object. Transitions in the light- dark box and percentage of center entries in the open-field and novel-object tests are not shown. Astressin-2B decreased anxiety-like behavior in the light- dark box, openfield, and novel-object tests in the stress condition but had little effect in the no-stress condition. In the light- dark box, 24 and 96 pmolofastressin-2Bdecreasedtheanxiogeniceffectofurocortin2inthestressconditionbuthadnoeffectinvehicle-treatedmice, whereasthe192pmoldosereducedanxietyinallstressedmice,decreasingthelatencytoenterthelightsideofthelight- darkbox ( a ) and increasing time spent in the light side ( b ). In the open field, 24 pmol of astressin-2B decreased the anxiogenic effect of urocortin 2 but had no effect in vehicle-treated mice in the stress condition ( d ). In the novel-object test, 24 and 96 pmol of the antagonist inhibited the anxiogenic effect of urocortin 2 but had no significant effect in vehicle-treated mice ( f ), whereas 192 pmol decreased anxiety in both groups. Data are presented as mean ± SEM. * p < 0.05; ** p < 0.01; *** p < 0.001.
Figure 7 CRF 2 antagonist astressin-2B blocked the effect of urocortin 2 and stress on anxiety. Effect of septal CRF 2 receptor antagonist astressin-2B (24, 96, or 192 pmol) administered 10 min before urocortin 2 (48 pmol) in CRF 2 receptor wild-type mice treated with no stress or 30 min of immobilization stress on the following: a , latency to enter the light side of the light- dark box (seconds); b , total time spent in the light side of the light- dark box (seconds); c , locomotionintheopenfield(totalsquareentries); d , percentage of time in the center of the open field; e , locomotion in the open field with a novel object (total square entries); and f , percentage of time spent in the center with a novel object. Transitions in the light- dark box and percentage of center entries in the open-field and novel-object tests are not shown. Astressin-2B decreased anxiety-like behavior in the light- dark box, openfield, and novel-object tests in the stress condition but had little effect in the no-stress condition. In the light- dark box, 24 and 96 pmolofastressin-2Bdecreasedtheanxiogeniceffectofurocortin2inthestressconditionbuthadnoeffectinvehicle-treatedmice, whereasthe192pmoldosereducedanxietyinallstressedmice,decreasingthelatencytoenterthelightsideofthelight- darkbox ( a ) and increasing time spent in the light side ( b ). In the open field, 24 pmol of astressin-2B decreased the anxiogenic effect of urocortin 2 but had no effect in vehicle-treated mice in the stress condition ( d ). In the novel-object test, 24 and 96 pmol of the antagonist inhibited the anxiogenic effect of urocortin 2 but had no significant effect in vehicle-treated mice ( f ), whereas 192 pmol decreased anxiety in both groups. Data are presented as mean ± SEM. * p < 0.05; ** p < 0.01; *** p < 0.001.CC-BY-NC-SA · From the PDF
Image 7
CC-BY-NC-SA · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. 10.1210/en.141.1.256 · DOI

Cited by

Sorted by citations

See all 147

Related

See all

Metadata

Authors
Henry, B., Vale, W., & Markou, A.
Affiliations
  • Scripps Research Institute (US)
  • Salk Institute for Biological Studies (US)
Corresponding author
Markou, Athina
ORCID
Vale, Wylie
Venue
The Journal of Neuroscience
Publisher
Society for Neuroscience
Published
2006-09-06
Volume
26
Issue
36
Pages
9142-9152
ISSN
  • 0270-6474 (ISSN-L)
  • 1529-2401
DOI
10.1523/jneurosci.1494-06.2006
PMC
PMC6674509
OpenAlex
W1996743601
Cited by
147
References
38
Citations by year
2026: 5 · 2025: 3 · 2024: 7 · 2023: 2 · 2022: 5 · 2021: 8 · 2020: 2 · 2019: 2 · 2018: 3 · 2017: 8 · 2016: 7 · 2015: 5 · 2014: 11 · 2013: 3 · 2012: 10
FWCI
5.57
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Neuroscience (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health
  • National Institute of Mental Health (U01 MH 69062, R01MH62527, U01MH069062, R01MH062527)
  • National Institute of Diabetes and Digestive and Kidney Diseases (DK 26741, P01DK026741)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
  • Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
corticotropin-releasing factor, CRF2 receptor, urocortin 2, antalarmin, lateral septum, anxiety, stress levels, restraint stress, CRF1 receptor, medial septum, dose dependence
MeSH terms
CRF Receptor, Type 1, Animals, Anxiety, Corticotropin-Releasing Hormone, Dose-Response Relationship, Drug, Injections, Intraventricular, Male, Mice, Inbred ICR, Stress, Psychological, Receptors, Corticotropin-Releasing Hormone, Mice, Knockout, Septum of Brain, Mice, Urocortins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review